ACCESS
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 200 patients (estimated)
- Tags
- Allogeneic Stem Cell Transplant, Myeloablative Conditioning (MAC), Nonmyeloablative Conditioning (NMA), Post-Allogeneic Stem Cell Transplant, Pre-Transplant, Reduced Intensity Conditioning (RIC)
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1268
- NCT Identifier
- NCT04904588
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.